Table 2. Clinical Improvements From Baseline to 3 Monthsa.
| Criteria | Median (IQR) | |
|---|---|---|
| FUS Thalamotomy (n = 20) |
Sham Procedure (n = 7) |
|
| CRSTb | ||
| Tremor subscore (CRST A+B), treated handc | 7 (3.5 to 14.0) | 2 (3.0 to 6.0) |
| Tremor subscore (CRST A+B), treated hand, %c | 62 (22.0 to 79.0) | 22 (−11.0 to 29.0) |
| Total CRST | 18 (12.0 to 25.0) | 3 (−4.0 to 17.0) |
| Total CRST, % | 44 (23.0 to 78.0) | 12 (−8.0 to 37.0) |
| UPDRS scores | ||
| Resting tremor (item 20), treated hand | 1.5 (0 to 3.0) | 0 (0 to 0) |
| Postural or action tremor (item 21), treated hand | 1 (0.5 to 2.5) | 0 (0 to 2.0) |
| Motor (part III) subsection | 8 (0.5 to 11.0) | 1 (−5.0 to 9.0) |
| Total UPDRS | 14 (6.5 to 16.0) | 3 (−3.0 to 13.0) |
| Quality of life | ||
| PDQ-39 score | 5.4 (−2.4 to 11.9) | 7.6 (0.9 to 13.0) |
| CRST disability (part C) score | 7.5 (1.0 to 12.5) | 3 (0 to 4.0) |
| Neuropsychological | ||
| MoCA scored | 0 (−1.5 to 2.5) | 1 (−1.0 to 2.0) |
| BDI-II scoree | 0 (−3.0 to 2.0) | 1 (−2.0 to 2.0) |
| LEDD, mg | 0 (0 to 150) | 0 (−200 to 0) |
Abbreviations: BDI-II, Beck Depression Inventory; CRST, Clinical Rating Scale for Tremor; FUS, focused ultrasound; IQR, interquartile range; LEDD, levodopa-equivalent daily dosage; MoCA, Montreal Cognitive Assessment; PDQ-39, 39-item Parkinson’s Disease Questionnaire; UPDRS, Unified Parkinson’s Disease Rating Scale.
All assessments were performed in the on-medication state. Positive improvements represent a decrease in score or dosage from baseline.
Scores for the CRST, UPDRS, and PDQ-39 are explained in the Outcomes subsection of the Methods section.
Predefined primary outcome.
Scores for the MoCA range from 0 to 30, with lower scores indicating impairment.
Scores for the BDI-II range from 0 to 63, with higher scores indicating more depressive symptoms.